Abstract Background: The anti-angiogenic Sorafenib is the only approved systemic therapy
for advanced hepatocellular carcinoma (HCC). However, acquired resistance limits its …

Sorafenib leads to a survival benefit in patients with advanced hepatocellular carcinoma but
its use is hampered by the occurrence of drug resistance. To investigate the molecular …

Objective Sorafenib is effective in hepatocellular carcinoma (HCC), but patients ultimately
present disease progression. Molecular mechanisms underlying acquired resistance are still …

Acquired evasive resistance is a major limitation of hepatocellular carcinoma (HCC)
treatment with the tyrosine kinase inhibitor (TKI) sorafenib. Recent findings suggest that …

Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis
and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC) …

Sorafenib, an orally-available kinase inhibitor, is the only standard clinical treatment against
advanced hepatocellular carcinoma. However, development of resistance to sorafenib has …

Sorafenib is a specific adenosine triphosphate–competitive RAF inhibitor used as a first‐line
treatment of advanced hepatocellular carcinoma (HCC). However, the responses are …

Sorafenib, the unique drug as first-line treatment for advanced hepatocellular carcinoma
(HCC), has opened a window of hope after searching for effective agents to combat HCC for …

Long‑term sorafenib treatment triggers resistance to chemotherapy in patients with
hepatocellular carcinoma (HCC). In order to investigate the mechanisms of sorafenib …

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality
worldwide. Sorafenib is the first multi-tyrosine kinase inhibitor approved for HCC and it has …